Protein Degradation Beyond PROTACs — PatSnap Eureka
Protein Degradation Beyond PROTACs: Molecular Glues, LYTACs & Autophagy
75–80% of the human proteome remains inaccessible to conventional drugs. Next-generation degradation platforms—molecular glues, LYTACs, AUTOTACs, AbTACs, and more—are unlocking this vast undruggable space across cancer, neurodegeneration, and immunology.
Why Conventional Drugs Fail 75–80% of Protein Targets
A substantial fraction of the human proteome—estimated in multiple sources as 75–80% of all protein targets—remains inaccessible to conventional small-molecule drugs due to the absence of catalytic pockets, the prevalence of scaffolding or transcription factor functions, or extracellular/membrane localization. Targeted protein degradation (TPD) has emerged as a transformative therapeutic paradigm to directly eliminate disease-causing proteins by hijacking endogenous cellular machinery.
Intracellular proteins such as BRD4, androgen receptor (AR), estrogen receptor (ER), BTK, BCR-ABL, CDK4/6, IRAK4, STAT3, Tau, MDM2, ENL, HDAC6, IDO1, YAP, PCNA, and WDR5 represent recurrent targets across the life sciences patent literature, largely in cancer and neurodegeneration contexts. Extracellular and membrane proteins including PD-L1, nucleolin, and transferrin receptor (TfR1) have emerged as targets for lysosomal degradation platforms.
Three principal degradation pathways are co-opted by these modalities: the ubiquitin-proteasome system (UPS) by PROTACs and molecular glues; the endo-lysosomal pathway by LYTACs and AbTACs for membrane and secreted proteins; and autophagy pathways—specifically autophagosome-lysosome fusion mediated by LC3—by AUTACs, ATTECs, and AUTOTACs. The NIH/PubMed literature continues to expand rapidly across all three axes.
Key E3 ligases cited across results include cereblon (CRBN), von Hippel-Lindau (VHL), MDM2, cIAP1, RNF114, RNF43, FEM1B, DCAF1, DCAF5, and the recently described UBE2D (an E2 ubiquitin-conjugating enzyme), reflecting concerted efforts to expand the E3 ligase toolbox beyond the dominant CRBN/VHL pair. Patent landscape analytics reveal that organizations controlling novel E3 ligase ligands occupy increasingly differentiated IP positions.
Nine TPD Platforms Reshaping Drug Discovery
From clinically validated PROTACs to emerging lysosomal chimeras and autophagy exploiters, each platform addresses a distinct segment of the previously undruggable proteome.
PROTACs (Proteolysis-Targeting Chimeras)
Heterobifunctional small molecules consisting of a target-binding ligand, a linker, and an E3 ligase-recruiting moiety. Upon forming a ternary complex, PROTACs promote polyubiquitination and subsequent proteasomal degradation. This "event-driven" pharmacology allows catalytic, substoichiometric activity. ARV-110 (AR-targeting) and ARV-471 (ER-targeting) have advanced to Phase I/II clinical trials for prostate and breast cancer, respectively.
~15 compounds in clinical trialsMolecular Glues
Small molecules that stabilize neo-substrate interactions with E3 ligase receptor proteins—most notably CRBN (via IMiDs such as pomalidomide, lenalidomide, thalidomide) and DCAF15 (via sulfonamides)—to promote degradation of context-specific neosubstrates. Unlike PROTACs, molecular glues do not require bifunctionality; they act by remodeling the surface of the E3 ligase. CRBN-directed IMiDs degrade IKZF transcription factors as canonical examples.
IMiDs clinically establishedLYTACs (Lysosome-Targeting Chimeras)
Bifunctional molecules designed to degrade extracellular and membrane-anchored proteins by co-opting internalizing cell-surface receptors to traffic targets to the lysosome. Original designs used glycopeptide conjugates engaging CI-M6PR/IGF2R or ASGPR. A 2023 next-generation LYTAC platform uses non-glycosylated IGF2 peptides targeting PD-L1 via the IGF2R/CI-M6PR lysosomal shuttling pathway, with efficacy exceeding anti-PD-L1 antibodies in vitro.
PD-L1 proof-of-conceptAbTACs & REULR
Fully recombinant bispecific antibodies that recruit membrane-bound E3 ligases (e.g., RNF43) for lysosomal degradation of cell-surface proteins—exemplified by PD-L1 degradation (UCSF, 2021). The complementary REULR nanobody platform (Stanford) generated cross-reactive nanobodies against five transmembrane PA-TM-RING E3 ligases (RNF218, RNF130, RNF167, RNF43, ZNRF3) to expand cell-surface target coverage.
5 E3 ligases covered by REULRAUTOTACs, ATTECs & AUTACs
Three distinct autophagy-leveraging platforms: AUTACs tag proteins with guanine-based degradation signals for selective autophagy; ATTECs interact with both LC3 and the target to tether it for autophagic degradation; AUTOTACs bind the ZZ domain of p62/SQSTM1, activating it into oligomeric bodies for sequestration. AUTOTAC simultaneously degrades targets and accelerates cellular autophagic flux—particularly relevant for aggregation-prone proteins such as mutant huntingtin.
Aggregation-prone protein targetsRiboPROTACs, RNA-PROTACs & BioPROTACs
Non-small-molecule degrader formats: RiboPROTACs use circular mRNA-encoded BioPROTAC proteins for intracellular delivery (demonstrated for GFP and PCNA, Suzhou CureMed 2022); RNA-PROTACs use small RNA mimics targeting RNA-binding protein sites conjugated to E3-recruiting peptides (LIN28, RBFOX1 degradation, ETH Zurich 2020); BioPROTACs are intracellular biologics for targets lacking high-affinity small-molecule binders (PCNA, MSD 2019).
Overcomes small-molecule binding limitsTPD Modality Landscape: Pathway Coverage & Development Stage
Patent and literature signals mapped across degradation pathways, development stages, and target classes.
TPD Modalities by Degradation Pathway
UPS-dependent platforms (PROTACs + molecular glues) dominate the retrieved dataset; lysosomal and autophagy platforms represent rapidly growing segments.
E3 Ligase Toolbox Expansion Beyond CRBN/VHL
Concerted efforts across academic and pharma institutions to validate novel E3 ligase recruiters, driven by CRBN resistance and tissue-specificity requirements.
Emerging Directions & Strategic Implications
Retrieved patent and literature signals reveal seven convergent directions shaping the next generation of TPD drug discovery.
Expanding the E3 Ligase Toolbox
Signals from Northwestern University, University of Dundee, UC San Diego, Novartis, and UC Berkeley indicate concerted efforts to move beyond CRBN and VHL toward FEM1B, RNF114, UBE2D, DCAF1, L3MBTL3, and at least 11 additional E3 ligases. This is motivated by tissue-specific E3 expression, acquired CRBN resistance, and off-target ZF protein degradation by pomalidomide-based PROTACs.
Spatial & Conditional Control: Photo-PROTACs & PhosphoTACs
Light-controllable PROTACs using photo-caging and photo-switch strategies achieve temporospatial degradation control, addressing on-target off-tissue toxicity concerns. PhosphoTACs represent a phosphorylation-responsive variant enabling conditional target degradation only in specific cellular states.
Complex Degradation Strategy
The MS147 example (University of North Carolina, 2022) signals a strategy where PROTAC binding to an interacting partner (EED) drives degradation of associated proteins (BMI1, RING1B), potentially enabling indirect targeting of proteins with no tractable ligand—a generalizable approach beyond single-protein targets.
Aptamer-PROTACs for Tumor-Selective Delivery
Spatioselective PROTACs using aptamers (AS1411 targeting nucleocytoplasmic shuttling proteins) for tumor-selective delivery represent signals toward tumor-targeted degradation, reducing systemic exposure. Nucleolin-targeting aptamer PROTAC ZL216 demonstrates cancer-selective delivery via differential cell-surface nucleolin expression.
Key Targets Across Intracellular & Extracellular TPD Platforms
Recurrent targets identified across retrieved patent and literature records, mapped by disease context and representative modality.
| Target | Disease Context | Representative Modality | Stage |
|---|---|---|---|
| AR (Androgen Receptor) | Prostate cancer | PROTAC — ARV-110 | Clinical Phase I/II |
| ER (Estrogen Receptor) | Breast cancer | PROTAC — ARV-471 | Clinical Phase I/II |
| BRD4 / BRD7 / BRD9 | Cancer (broad) | PROTACs — VZ185, MZ1, SIM1 (VHL-based) | Preclinical |
| BTK | B-cell malignancies | Reversible/covalent PROTACs | Clinical |
| BCR-ABL | CML | Nimbolide/RNF114-recruiting PROTAC (BT1) | Preclinical |
| ENL | MLL-rearranged leukemia, Wilms tumor | PROTAC (super elongation complex) | Preclinical |
| HDAC6 | Multiple myeloma | PROTAC — NP8 | Preclinical |
| IKZF transcription factors | Hematologic malignancies | Molecular Glues — IMiDs (CRBN-directed) | Clinically Established |
Identify Competitive IP Positions in TPD
PatSnap Eureka maps assignee clusters, E3 ligase IP, and clinical pipeline gaps in real time
Who Is Leading TPD Innovation?
In this dataset, innovation is predominantly literature-driven (academic papers), with a smaller but notable patent signal. Yale University (Craig Crews laboratory) contributes multiple foundational papers on PROTAC history, LYTACs, ENDTACs, and methyl reader-hijacking nuclear degradation strategies—cited across at least 4 retrieved results. The University of Dundee (MRC Protein Phosphorylation and Ubiquitylation Unit) contributes structural basis of PROTAC ternary complex cooperativity, BRD7/BRD9 degrader optimization, and E3 ligase ligand discovery—also cited across at least 4 retrieved results.
Stanford University contributes endolysosomal degradation reviews, the REULR nanobody-based toolbox, and TransTACs (2023). UC Berkeley reports the FEM1B covalent recruiter discovery and nimbolide/RNF114-based BCR-ABL degrader. Novartis Institutes for BioMedical Research describes a novel E2 ubiquitin conjugating enzyme (UBE2D) recruiter via covalent chemoproteomics. The WIPO patent database and European Patent Office filings reflect growing industry interest in protecting these platforms.
On the industry side, Boehringer Ingelheim contributes VHL-based BRD9 degrader optimization (VZ185); MSD (Merck) develops the BioPROTAC biologics platform for PCNA; Bayer AG contributes a comprehensive medicinal chemistry review of TPD including molecular glues; and Suzhou CureMed Biopharma Technology describes the RiboPROTAC mRNA delivery platform. The dataset reflects a field where academic institutions lead mechanistic discovery, with pharmaceutical companies beginning to translate into optimized degraders and novel recruiters. PatSnap customers in pharma use these signals to identify partnership and licensing opportunities.
Patent assignee signals are currently sparse for LYTAC and AbTAC platforms—academic literature dominates early innovation—suggesting significant opportunity for IP estate development around receptor-ligand conjugates, linker chemistries, and internalizing receptor utilization. PatSnap analytics can surface these white spaces systematically. The FDA's emerging therapy guidance is also relevant context for developers planning IND-enabling studies for these novel modalities.
Protein Degradation Beyond PROTACs — key questions answered
A substantial fraction of the human proteome—estimated in multiple sources as 75–80% of all protein targets—remains inaccessible to conventional small-molecule drugs due to the absence of catalytic pockets, the prevalence of scaffolding or transcription factor functions, or extracellular/membrane localization.
Unlike PROTACs, molecular glues do not require bifunctionality; they act by remodeling the surface of the E3 ligase to recognize proteins not normally ubiquitinated. Molecular glues are small molecules that stabilize neo-substrate interactions with E3 ligase receptor proteins—most notably CRBN and DCAF15—to promote degradation of context-specific neosubstrates.
ARV-110 (AR-targeting) and ARV-471 (ER-targeting) have advanced to Phase I/II clinical trials for prostate and breast cancer, respectively, representing clinical proof-of-concept. Approximately 15 PROTACs against various targets are currently tested in clinical trials, with candidates including those targeting AR, ER, BTK, BRD4, IRAK4, and others.
LYTACs (Lysosome-Targeting Chimeras) are bifunctional molecules designed to degrade extracellular and membrane-anchored proteins by co-opting internalizing cell-surface receptors to traffic targets to the lysosome. Original LYTAC designs used glycopeptide conjugates engaging the cation-independent mannose-6-phosphate receptor (CI-M6PR/IGF2R) or the asialoglycoprotein receptor (ASGPR). A next-generation LYTAC platform uses non-glycosylated IGF2 peptides targeting PD-L1 via the IGF2R/CI-M6PR lysosomal shuttling pathway, with efficacy exceeding anti-PD-L1 antibodies in vitro.
Autophagy-based degraders include AUTACs, ATTECs, and AUTOTACs. AUTACs tag proteins with guanine-based degradation signals to engage selective autophagy. ATTECs interact with both LC3 and the target protein to tether the target for autophagic degradation. AUTOTACs bind the ZZ domain of the autophagy receptor p62/SQSTM1, activating it into oligomeric bodies for sequestration and degradation. These approaches are particularly relevant for aggregation-prone proteins such as mutant huntingtin resistant to proteasomal clearance.
Organizations controlling novel, well-validated ligands for under-exploited E3 ligases (FEM1B, RNF114, UBE2D, DCAF1) will occupy differentiated IP positions, particularly as CRBN resistance mechanisms emerge clinically with IMiD-based degraders. E3 ligase diversification is motivated by tissue-specific E3 expression, acquired CRBN resistance, and off-target ZF protein degradation by pomalidomide-based PROTACs.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About TPD PlatformsUnlock the Full Targeted Protein Degradation Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from PROTAC IP landscapes to LYTAC white space analysis.
References
- Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs — Department of Pharmacology, Yale University, 2021
- Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins — University of Mississippi, 2021
- PROTAC targeted protein degraders: the past is prologue — Craig Crews, Yale University, 2022
- The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system — University of Louisville, 2022
- Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway — Stanford University, 2021
- Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 — University of California San Francisco, 2021
- Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox — Stanford University, 2022
- IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins — Recepton Sp. z o.o., 2023
- Circular mRNA encoded PROTAC (RiboPROTAC) as a new platform for the degradation of intracellular therapeutic targets — Suzhou CureMed Biopharma, 2022
- RNA-PROTACs: Degraders of RNA-Binding Proteins — ETH Zurich, 2020
- bioPROTACs as versatile modulators of intracellular therapeutic targets — MSD, 2019
- Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs) — Yale University, 2019
- Modeling the Degradation Effects of Autophagosome Tethering Compounds (ATTEC) — Fudan University, 2020
- Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings — Ridgeline Discovery, 2023
- Recent Advances of Degradation Technologies Based on PROTAC Mechanism — Shandong Second Provincial General Hospital, 2022
- WIPO — World Intellectual Property Organization: Global patent database for TPD-related filings
- European Patent Office (EPO) — Patent search and analytics for European TPD IP landscape
- NIH/PubMed — National Center for Biotechnology Information: Primary literature source for TPD research
- U.S. Food and Drug Administration (FDA) — Emerging therapy guidance relevant to novel TPD modalities
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within a retrieved patent and literature dataset and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.